← Leaderboards
Francesca Catella-Lawson
University Of Pennsylvania
$1,843,768
Attributed
$1,843,768
Total exposure
6
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,843,768 · 6
By mechanism
M01$1,843,768 · 6
Top collaborators
No co-investigators on record.
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Joel S. Bennett$17,907,964
- Garret A Fitzgerald$242,218,424
- Emer Maria Smyth$2,881,375
- Richard Assoian$21,573,073
- Daniel James Rader$77,348,993
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchUrinalysisGas Chromatography Mass SpectrometryPharmacokineticsAspirinPlatelet Aggregation InhibitorsOxidative StressAtherosclerosisArachidonateDisease /Disorder Proneness /RiskGlycosylationDiabetic AngiopathyDrug InteractionsLow Density LipoproteinDiabetes MellitusFibrinogen ReceptorsIndomethacinElectrospray Ionization Mass SpectrometryBlood Vessel OcclusionFree RadicalsEicosanoidsCopperEicosanoid Metabolism
Grant awards (30)
OXIDATIVE STRESS AND ATHEROSCLEROTIC COMPLICATIONS OF DIABETES$124,146
M01 · FY2002 · RR
SELECTIVE INHIBITION OF CYCLOOXYGENASE-2 IN ATHEROSCLEROSIS$124,146
M01 · FY2002 · RR
METABOLISM OF 8 EPI PGF2 IN HEALTHY VOLUNTEERS$124,146
M01 · FY2002 · RR
PHARMACODYNAMIC INTERACTION: GPIIB/IIIA ANTAGONIST/ASPIR$124,146
M01 · FY2002 · RR
SELECTIVE INHIBITION OF CYCLOOXYGENASE-2 IN ATHEROSCLEROSIS$124,146
M01 · FY2001 · RR
OXIDATIVE STRESS AND ATHEROSCLEROTIC COMPLICATIONS OF DIABETES$124,146
M01 · FY2001 · RR
METABOLISM OF 8 EPI PGF2 IN HEALTHY VOLUNTEERS$124,146
M01 · FY2001 · RR
PHARMACODYNAMIC INTERACTION: GPIIB/IIIA ANTAGONIST/ASPIR$124,146
M01 · FY2001 · RR
METABOLISM OF 8 EPI PGF2 IN HEALTHY VOLUNTEERS$0
M01 · FY2001 · RR
SELECTIVE INHIBITION OF CYCLOOXYGENASE-2 IN ATHEROSCLEROSIS$0
M01 · FY2001 · RR
PHARMACODYNAMIC INTERACTION: GPIIB/IIIA ANTAGONIST/ASPIR$0
M01 · FY2001 · RR
OXIDATIVE STRESS AND ATHEROSCLEROTIC COMPLICATIONS OF DIABETES$0
M01 · FY2001 · RR
PHARMACODYNAMICS, &PLASMA CONCENTRATION PROFILE OF L 734,217$187,536
M01 · FY2000 · RR
RPR 109891 ORALLY FOR 8 WEEKS IN PTS WITH RECENT ACUTE CORONARY ARTERY SYNDROMES$187,536
M01 · FY2000 · RR
RPR 109891 ORALLY FOR 8 WEEKS IN PTS WITH RECENT ACUTE CORONARY ARTERY SYNDROMES$187,536
M01 · FY2000 · RR
PHARMACODYNAMICS, &PLASMA CONCENTRATION PROFILE OF L 734,217$187,536
M01 · FY2000 · RR
OXIDATIVE STRESS AND ATHEROSCLEROTIC COMPLICATIONS OF DIABETES$25,114
M01 · FY2000 · RR
RPR 109891 ORALLY FOR 8 WEEKS IN PTS WITH RECENT ACUTE CORONARY ARTERY SYNDROMES$25,114
M01 · FY2000 · RR
METABOLISM OF 8 EPI PGF2 IN HEALTHY VOLUNTEERS$25,114
M01 · FY2000 · RR
PHARMACODYNAMICS, &PLASMA CONCENTRATION PROFILE OF L 734,217$25,114
M01 · FY2000 · RR
SELECTIVE INHIBITION OF CYCLOOXYGENASE-2 IN ATHEROSCLEROSIS$0
M01 · FY2000 · RR
METABOLISM OF 8 EPI PGF2 IN HEALTHY VOLUNTEERS$0
M01 · FY2000 · RR
METABOLISM OF 8 EPI PGF2 IN HEALTHY VOLUNTEERS$0
M01 · FY2000 · RR
PHARMACODYNAMIC INTERACTION: GPIIB/IIIA ANTAGONIST/ASPIR$0
M01 · FY2000 · RR
OXIDATIVE STRESS AND ATHEROSCLEROTIC COMPLICATIONS OF DIABETES$0
M01 · FY2000 · RR
PHARMACODYNAMIC INTERACTION: GPIIB/IIIA ANTAGONIST/ASPIR$0
M01 · FY2000 · RR
PHARMACODYNAMIC INTERACTION: GPIIB/IIIA ANTAGONIST/ASPIR$0
M01 · FY2000 · RR
OXIDATIVE STRESS AND ATHEROSCLEROTIC COMPLICATIONS OF DIABETES$0
M01 · FY2000 · RR
SELECTIVE INHIBITION OF CYCLOOXYGENASE-2 IN ATHEROSCLEROSIS$0
M01 · FY2000 · RR
SELECTIVE INHIBITION OF CYCLOOXYGENASE-2 IN ATHEROSCLEROSIS$0
M01 · FY2000 · RR